Search

Xini Zhang

from Bridgewater, NJ
Age ~62
Get Report
Also known as:
Zhang Xini
Phone and address:
1701 Bayley Ct, Bridgewater, NJ 08807
(908) 252-1188
Related to:
Yun Fu Yang, 83Lijun Zhang, 41Yi L Li, 55Kai Hu, 50Runsheng Wang, 45Cindy X Zhang, 52Tony Zhang, 56Chuanfang ZhangDaniel N Zhang, 35
Connected to:
Aaron N Zhang, 60Adelaide X Zhang, 48Aiai Zhang, 38Aijun Zhang, 70Airong Zhang, 71Alfred Zhang, 30Anderson Zhang, 34Angeline Zhang, 36Anli Zhang, 68Anming Zhang, 64

Xini Zhang Phones & Addresses

  • 1701 Bayley Ct, Bridgewater, NJ 08807 (908) 252-1188
  • Jersey City, NJ
  • Smyrna, DE
  • Green Brook, NJ
  • Cary, NC
  • Wade, NC
  • Jericho, NY
  • 1009 Shadowlawn Dr, Green Brook, NJ 08812 (908) 252-1188

Work

Position: Building and Grounds Cleaning and Maintenance Occupations

Education

Degree: Graduate or professional degree

Business Records

Name / Title
Company / Classification
Phones & Addresses
Xini Zhang
Manager
XZ REALTY LLC
1009 Shadowlawn Dr, Dunellen, NJ 08812
389 Washington St, Jersey City, NJ 07302

Publications

Us Patents

Compositions And Methods For Advanced Glycosylation Endproduct-Mediated Modulation Of Amyloidosis

View page
US Patent:
6410598, Jun 25, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/477364
Inventors:
Michael P. Vitek - Apex NC, 27502
Anthony Cerami - Shelter Island NY, 11964
Richard J. Bucala - New York NY, 10021
Peter C. Ulrich - Old Tappan NJ, 07675
Helen Vlassara - Shelter Island NY, 11964
Xini Zhang - Jericho NY, 11753
International Classification:
A01N 3752
US Classification:
514632, 514634, 514 20, 5142298, 514331
Abstract:
The present invention relates generally to the non-enzymatic glycosylation of amyloidogenic proteins and the consequent formation of advanced glycosylation endproducts (AGEs). It has been found that formation of AGE-amyloidogenic proteins can enhance amyloidosis. The invention further relates to compositions and methods for the prevention and treatment of amyloidosis associated with amyloid diseases, particularly neurodegenerative disease and Type II diabetes, and more particularly Alzheimers disease. In a specific example, aggregation of an amyloidogenic peptide, AP, is enhanced by the glycosylation reaction of AP to form AGE-AP as defined herein. Accordingly, the invention extends to a method for modulating the in vivo aggregation of amyloid polypeptides and associated amyloidosis by controlling the formation and presence of AGE-amyloid polypeptide. A corresponding diagnostic utility comprises the measurement of the course and extent of amyloidosis by a measurement of the presence and amount of AGEs and particularly, AGE-amyloid. An assay is included that may use the AGE-amyloid polypeptide of the present invention to identify disease states characterized by the presence of AGE-amyloid.

N-[2-[[(Diaminomethylene)Amino]Oxy]Ethyl]-3-[(2,2-Difluoro-2-Phenylethyl)Amino]-6-Methyl-2-Oxo-1(2H)-Pyrazineacetamide

View page
US Patent:
20080021044, Jan 24, 2008
Filed:
May 21, 2007
Appl. No.:
11/751155
Inventors:
Mitul Patel - Union NJ, US
Christopher Nilsen - Branchburg NJ, US
Mayra Reyes - Somerset NJ, US
Michael Humora - Cranbury NJ, US
Yun Qian - Doylestown PA, US
Fuqiang Liu - Lansdale PA, US
Xini Zhang - Bridgewater NJ, US
Kirk Sorgi - Doylestown PA, US
International Classification:
A61K 31/4965
A61P 7/02
C07D 241/08
US Classification:
514255060, 544408000
Abstract:
The present invention is directed to N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-s-oxo-1(2H)-pyrazineacetamide, pharmaceutical compositions containing said compound and methods of treatment comprising inhibiting a serine protease using said compound. The present invention is further directed to a process for the preparation of the N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide as a free base. The present invention is further directed to a process for the preparation of pharmaceutically acceptable salts of N-[2-[[(aminoiminomethyl)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide.

3-Alkylamino-2-Hydroxy-4-Hydroxymethyl-2-Cyclopenten-1-One Advanced Glycosylation Endproducts And Methods Of Use Therefor

View page
US Patent:
56886535, Nov 18, 1997
Filed:
Jun 27, 1996
Appl. No.:
8/673217
Inventors:
Peter C. Ulrich - Old Tappan NJ
Xini Zhang - Wilmington DE
Assignee:
The Picower Institute for Medical Research - Manhasset NY
International Classification:
G01N 3353
C07C20500
C07K 1600
US Classification:
435 71
Abstract:
The present invention relates to advanced glycosylation endproducts (AGEs), and particularly to novel cyclopentenone aminoreductones, 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-ones. Such AGEs can be used in various diagnostic and therapeutic methods.

3-Alkylamino-2-Hydroxy-4-Hydroxymethyl-2-Cyclopenten-1-One Advanced Glycosylation Endproducts And Methods Of Use Therefor

View page
US Patent:
58146644, Sep 29, 1998
Filed:
Jun 23, 1997
Appl. No.:
8/880565
Inventors:
Peter C. Ulrich - Old Tappan NJ
Xini Zhang - Hoover AL
Assignee:
Picower Institute for Medical Research - Manhasset NY
International Classification:
G01N 3353
US Classification:
514579
Abstract:
The present invention relates to advanced glycosylation endproducts, and particularly to the use of novel cyclopentenone aminoreductones, 3-alkylamino-2 -hydroxy-4-hydroxymethyl-2-cyclopenten-1-ones. Such AGEs can be used in various diagnostic and therapeutic methods.
Control profile
Xini Zhang from Bridgewater, NJ, age ~62 Get Report